Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 663* | 2021 |
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells P Neviani, JG Harb, JJ Oaks, R Santhanam, CJ Walker, JJ Ellis, ... The Journal of clinical investigation 123 (10), 4144-4157, 2013 | 259 | 2013 |
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma A Chaidos, CP Barnes, G Cowan, PC May, V Melo, E Hatjiharissi, ... Blood, The Journal of the American Society of Hematology 121 (2), 318-328, 2013 | 163 | 2013 |
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies P Neelakantan, G Gerrard, C Lucas, D Milojkovic, P May, L Wang, ... Blood, The Journal of the American Society of Hematology 121 (14), 2739-2742, 2013 | 113 | 2013 |
Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells HW Auner, AM Moody, TH Ward, M Kraus, E Milan, P May, A Chaidos, ... PloS one 8 (9), e74415, 2013 | 66 | 2013 |
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia A Bazeos, D Marin, AG Reid, G Gerrard, D Milojkovic, PC May, ... Leukemia 24 (6), 1243-1245, 2010 | 64 | 2010 |
Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing PC May, N Foot, R Dunn, H Geoghegan, MJ Neat Cancer genetics and cytogenetics 198 (1), 71-75, 2010 | 42 | 2010 |
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors M Daghistani, D Marin, JS Khorashad, L Wang, PC May, C Paliompeis, ... Blood, The Journal of the American Society of Hematology 116 (26), 6014-6017, 2010 | 37 | 2010 |
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating … G Silvestri, R Trotta, L Stramucci, JJ Ellis, JG Harb, P Neviani, S Wang, ... Blood cancer discovery 1 (1), 48-67, 2020 | 33 | 2020 |
High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study. SM Yule, NK Foreman, C Mitchell, N Gouldon, P May, HP McDowell Journal of clinical oncology 15 (10), 3258-3265, 1997 | 26 | 1997 |
Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma J Alvarez-Benayas, N Trasanidis, A Katsarou, K Ponnusamy, A Chaidos, ... Nature communications 12 (1), 5450, 2021 | 25 | 2021 |
Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3, 7, 8 and unipaternal disomy of chromosome 11 NJ Sebire, PC May, B Kaur, MJ Seckl, RA Fisher Diagnostic Pathology 11, 1-8, 2016 | 24 | 2016 |
Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B cell precursors B Boulianne, ME Robinson, PC May, L Castellano, K Blighe, J Thomas, ... Cell Reports 18 (7), 1687-1698, 2017 | 18 | 2017 |
Secondary parkinsonism: An unusual late complication of craniospinal radiotherapy given to a 16‐month child JA Skiming, HP McDowell, N Wright, P May Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 2003 | 17 | 2003 |
Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control AG Rowan, P May, A Badhan, C Herrera, P Watber, R Penn, MA Crone, ... Journal of Virological Methods 294, 114174, 2021 | 15 | 2021 |
Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality AJ Innes, P Woolley, RM Szydlo, S Lozano, F Fernando, D Bansal, ... Leukemia 34 (2), 667-670, 2020 | 12 | 2020 |
Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of BRCA1 and MSH2 missense variants L Loong, C Cubuk, S Choi, S Allen, B Torr, A Garrett, C Loveday, M Durkie, ... Genetics in Medicine 24 (3), 552-563, 2022 | 6 | 2022 |
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. P Neelakantan, K Rezvani, P May, G Gerrard, B Marco, C Paliompeis, ... British journal of haematology 164 (4), 2014 | 6 | 2014 |
T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow KN Naresh, PC May, AG Reid, AJ Marks, D Macdonald, E Kanfer Histopathology 57 (4), 549-554, 2010 | 5 | 2010 |
Three distinct hematological malignancies from a single germ cell tumor: a case report M Spencer Chapman, PC May, E Olavarria, E Nadal Melsio Journal of Medical Case Reports 14, 1-7, 2020 | 4 | 2020 |